Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy ; day:21 ; month:3 ; year:2024 ; pages:1-8
Neurological sciences ; (21.3.2024), 1-8
- Urheber
-
Pensato, Umberto
Pondrelli, Federica
Philippis, Chiara de
Asioli, Gian Maria
Crespi, Alessandra
Buizza, Alessandro
Mannina, Daniele
Casadei, Beatrice
Maffini, Enrico
Straffi, Laura
Marcheselli, Simona
Zinzani, Pier Luigi
Bonifazi, Francesca
Guarino, Maria
Bramanti, Stefania
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10072-024-07481-0
- URN
-
urn:nbn:de:101:1-2406182103004.011892337378
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pensato, Umberto
- Pondrelli, Federica
- Philippis, Chiara de
- Asioli, Gian Maria
- Crespi, Alessandra
- Buizza, Alessandro
- Mannina, Daniele
- Casadei, Beatrice
- Maffini, Enrico
- Straffi, Laura
- Marcheselli, Simona
- Zinzani, Pier Luigi
- Bonifazi, Francesca
- Guarino, Maria
- Bramanti, Stefania
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Psychiatric implications of anti-seizure medications in epileptic population
Seizure prophylaxis in the neuroscience intensive care unit
Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo
Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie
Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning
Seizure Management and Prophylaxis Considerations in Patients with Brain Tumors
Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Psychiatric implications of anti-seizure medications in epileptic population
Seizure prophylaxis in the neuroscience intensive care unit
Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo
Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie
Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning
Seizure Management and Prophylaxis Considerations in Patients with Brain Tumors
Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Psychiatric implications of anti-seizure medications in epileptic population
Seizure prophylaxis in the neuroscience intensive care unit
Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo
Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy
Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie
Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning